gip/glp 1-agonist tirzepatide GLP-1/GIP dual agonist normalizes diabetic nephropathy via PI3K/AKT mediated suppression of oxidative stress New Weight-Loss Drugs Are Poised

Semaglutide failed to provide benefit for either tumor growth or antigen presentation when it was discontinued prior to tumor cell injection in a metastatic melanoma model (63)

doi: 10.1016/j.biopha.2018.08.088 23 AstJArvanitiAFineNHFNasteskaDAshfordFBStamatakiZet al

Other important contributing factors are eating disorders and depression, which are more common in patients with T1D compared to the overall population (18, 19)

For tirzepatide, patients should be advised that oral contraceptive effectiveness may be reduced during initiation and dose escalation

Accessed 15 Oct 2018

Biosimilars Under the Medical Benefit 6.5